OTLK Stock Falls on Failure to Meet Non-Inferiority Goal in AMD Study
Portfolio Pulse from
Outlook Therapeutics' stock plummeted by 65% after its drug ONS-5010 failed to meet the non-inferiority endpoint in a study for wet AMD.
November 28, 2024 | 4:45 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Outlook Therapeutics' stock fell 65% due to the failure of its drug ONS-5010 to meet the non-inferiority endpoint in a study for wet AMD.
The failure of ONS-5010 to meet the non-inferiority endpoint is a significant setback for Outlook Therapeutics, leading to a 65% drop in stock price. This indicates a major loss of investor confidence and potential future challenges in the drug's development.
CONFIDENCE 100
IMPORTANCE 90
RELEVANCE 100